Plus Therapeutics (PSTV) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Plus Therapeutics Inc : Jonestrading Cuts Target Price to $10 From $32
ReutersNov 18 07:13 ET
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Yahoo FinanceNov 17 08:36 ET
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 16 11:33 ET · Ratings
Positive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy Rating
TipRanksNov 16 10:45 ET · Ratings
Plus Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow JonesNov 15 07:30 ET · Ratings
Plus Therapeutics Analyst Ratings
BenzingaNov 15 07:18 ET · Ratings

Comments

Jaguar8

Oct 1 06:31

NEWS

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy
Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy
ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New Y...

1

151479178

Sep 7 04:05

What’s the NASDAQ non compliance thing about on Sep 5???

$Plus Therapeutics (PSTV.US)$

Stock Region

Aug 13 11:52

Clinical-stage Therapeutics Company Presents Positive Clinical Trial Results

Plus Therapeutics Announces Encouraging Clinical Trial Outcomes at the 2024 SNO/ASCO CNS Metastases Conference.
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently presented promising data from their ReSPECT-LM clinical trial at the 2024 Society for Neuro-Oncology (SNO) and American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The trial focuses on evaluating the sa...

Jaguar8

Aug 13 08:22

NEWS

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide in...

1

Trytosaveabit

Aug 12 06:34

Update

$Plus Therapeutics (PSTV.US)$ Benzinga· 1 min ago
Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference

1

PSTV Plus Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target